当前位置:首页  科技动态  学术报告

10月17日 黄力夫教授讲座信息

时间:2019-10-11浏览:10

中医药交叉科学前沿论坛

报告题目Ratiometric Co-loading and Co-delivery of Drugs in Nanoparticles for Cancer Therapy

时间:20191017日(周四)9:30

地点:全球合作伙伴中心报告厅

报告人:黄力夫 教授




黄力夫教授Leaf Huang, Ph.D. is the Fred Eshelman Distinguished Professor, Division of Pharmacoengineering and Molecular Pharmaceutics in the Eshelman School of Pharmacy, University of North Carolina at Chapel Hill. Dr. Huang’s research has been in the area of gene therapy and targeted drug delivery. He has pioneered the liposome non-viral vector and has designed and manufactured the cationic lipid vector for the first non-viral clinical trial in 1992. His current work centers on nanoparticle vectors for gene transfer in tumor and liver. He also continues research in establishing a ligand targeted delivery system for cDNA, mRNA, siRNA, proteins and peptides for tumor growth inhibition and for vaccines in treating cancer and infected diseases.  He has authored or co-authored more than 600 papers with an H-index of 121. He is also the inventor or co-inventor of 22 US and foreign patents. In 2004, he received the Alec D. Bangham MD FRS Achievement Award, which is the highest honor in liposome research. He was the recipient of the 2013 Distinguished Pharmaceutical Scientist Award which is the highest scientific recognition of the American Association of Pharmaceutical Scientists. He was named a Highly Cited Researcher in “Pharmacology & Toxicology” since 2016. Dr. Huang has also co-founded 6 biotech start-ups in the past.


报告摘要Combination therapy is a routine practice in cancer therapy. Due to difference in PK and biodistribution of drugs, precise prediction of optimal dose and dosing schedule has been challenging. Prof. Huang will describe the theory and the practice of ratiometric co-loading and co-delivery of two or more drugs in nanoparticles for optimal efficacy and minimal toxicity. Emphasis will be drug combinations to induce immunogenic cell death for immunotherapy of cancer.


返回原图
/